Cargando…

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer

Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Henrica M. J., Trovik, Jone, Halle, Mari K., Wik, Elisabeth, Akslen, Lars A., Birkeland, Even, Bredholt, Therese, Tangen, Ingvild L., Krakstad, Camilla, Salvesen, Helga B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934991/ https://www.ncbi.nlm.nih.gov/pubmed/24587245 http://dx.doi.org/10.1371/journal.pone.0090141

Ejemplares similares

Androgen receptor as potential therapeutic target in metastatic endometrial cancer
por: Tangen, Ingvild Løberg, et al.
Publicado: (2016)

Switch in FOXA1 Status Associates with Endometrial Cancer Progression
por: Tangen, Ingvild Løberg, et al.
Publicado: (2014)

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer
por: Kusonmano, Kanthida, et al.
Publicado: (2018)

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses
por: Bredholt, Geir, et al.
Publicado: (2015)

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer
por: Mjos, Siv, et al.
Publicado: (2017)

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
por: Mauland, Karen Klepsland, et al.
Publicado: (2016)

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
por: Hoivik, Erling A., et al.
Publicado: (2014)

High visceral fat percentage is associated with poor outcome in endometrial cancer
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
por: Krakstad, Camilla, et al.
Publicado: (2015)

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers
por: Berg, Anna, et al.
Publicado: (2017)

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer
por: Berg, Anna, et al.
Publicado: (2016)

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
por: Engerud, Hilde, et al.
Publicado: (2019)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients
por: Berg, Anna, et al.
Publicado: (2014)

Blood Metabolites Associate with Prognosis in Endometrial Cancer
por: Strand, Elin, et al.
Publicado: (2019)

Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients
por: Tangen, Ingvild L, et al.
Publicado: (2017)

Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
por: Raeder, Maria B., et al.
Publicado: (2013)

Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease
por: Lien, Hilde E., et al.
Publicado: (2023)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma
por: Berg, Hege F., et al.
Publicado: (2020)

Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups
por: Askeland, Cecilie, et al.
Publicado: (2020)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
por: Karlsson, Thomas, et al.
Publicado: (2016)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer
por: Stefansson, Ingunn M., et al.
Publicado: (2015)

Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer
por: Wagner-Larsen, Kari S., et al.
Publicado: (2022)

Whole‐Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

Preoperative Tumor Size at MRI Predicts Deep Myometrial Invasion, Lymph Node Metastases, and Patient Outcome in Endometrial Carcinomas
por: Ytre-Hauge, Sigmund, et al.
Publicado: (2015)

Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
por: Lura, Njål, et al.
Publicado: (2022)

Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value
por: Berg, Hege F., et al.
Publicado: (2022)

MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer
por: Dybvik, Julie Andrea, et al.
Publicado: (2022)

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
por: Gibson, William J., et al.
Publicado: (2016)

Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study
por: Njølstad, Tormund S., et al.
Publicado: (2017)

Lipocalin 2 expression is associated with aggressive features of endometrial cancer
por: Mannelqvist, Monica, et al.
Publicado: (2012)

Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
por: Lindemann, Kristina, et al.
Publicado: (2021)

Preoperative pelvic MRI and 2-[(18)F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer—time to revisit current imaging guidelines?
por: Fasmer, Kristine E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_onus12pjhpo0fk9qro22v8nkff